Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Amulirafusp, an antibody targeting CD20.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Amostomig, an antibody targeting IAP × PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bexatamig, an antibody targeting IL3RA × NCR1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Safimestomig, an antibody targeting IAP × PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Turenkibart, an antibody targeting IL-17A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Velinotamig, an antibody targeting BCMA × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Marlotamig, an antibody targeting EGFR × CD28.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nebokitug, an antibody targeting CCL24.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ruxoprubart, an antibody targeting CFB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Imzokitug, an antibody targeting CCR8.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Eltivutabart, an antibody targeting ENTPD1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Exlinkibart, an antibody targeting 4-1BB.